Search Medical Condition
Please enter condition
Please choose location from dropdown

Hepatitis C; Chronic Clinical Trials

A listing of Hepatitis C; Chronic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (113) clinical trials

People with Hepatitis C Virus are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

The body’s immune system usually becomes active when the body is fighting off an infection or disease. If an immune system is active for a long period of time, it may lead to problems such as heart, liver, and kidney disease. Many people who inject drugs are also infected with ...

Phase N/A

Hepatitis C is an infectious disease affecting primarily the liver, caused by the hepatitis C virus (HCV). HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment and transfusions. An estimated 150-200 million people worldwide are infected with hepatitis C. The infection is often ...

Phase N/A

To explore the antiviral efficacy of combination therapy with sofosbuvir/ledipasvir fixed-dose combination ribavirin for 12 or 24 weeks in patients with advanced liver disease. Study designed with A cohort and B cohort.

Phase N/A

The purpose of this study is to evaluate the safety and effectiveness of an FDA-approved study drug as a sleep aid as compared to placebo (an inactive substance) in the treatment of insomnia associated with interferon-induced insomnia in patients with chronic hepatitis C (CHC). In addition, another purpose of this ...

Phase N/A

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

The capacity to scale-up interferon-free DAA therapy would be enhanced by simplified treatment monitoring strategies. The "next generation" DAA regimen of glecaprevir (300mg)/pibrentasvir (120mg), a protease inhibitor and NS5A inhibitor, provides key features for HCV treatment simplification, including on-treatment monitoring: 1) pangenotypic activity with extremely high efficacy (SVR>95%); 2) no ...


"Real Life" Evaluation of Efficacy and Safety of DAAs for the Treatment of HCV in Egypt

Clinical trials are performed under optimal conditions where patients are highly selected with no co-morbidity, clinical supervision is provided by the best specialists in the field, and strict protocols are used to enhance patients' compliance. Thus, results may not be generalizable to real-world clinical practice. Observational studies are now gaining ...

Phase N/A

Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence

Hepatitis C virus (HCV) is a preventable and curable blood-borne virus. Adherence to HCV therapies is essential to achieve sustained virologic response (SVR) or cure. New direct-acting agents (DAA) are now available, such as fixed-dose combination of ledipasvir and sofosbuvir, which is given once daily with or without ribavirin to ...

Phase N/A

'Fibrosis in the Lost Hepatitis C Population - Track Trace and Treat'

Objective To coordinate active tracing of chronic hepatitis C patients lost to follow-up to inform them about there disease severity and treatment options. Study design: This is a prospective cohort study, which will start as a pilot study in the Radboudumc Population: lost to follow-up chronic hepatitis C patients in ...

Phase N/A

Re-treatment of HCV Following DAA Failure

-Introduction Oral drugs, termed collectively as 'Direct-acting anti-viral agents' (DAAs), are the standard-of-care for HCV treatment. In India, four DAAs, namely sofosbuvir (SOF), daclatasvir (DCV), ledipasvir (LDV) and velpatasvir (VEL), are marketed. Initially, people were treated using SOF in combination with ribavirin with or without pegylated-interferon (Peg-IFN). Thereafter, HCV treatment ...

Phase N/A